Siemens’ PETNET Solutions receives ANDA approval for PET radiopharmaceutical

Siemens’ PETNET Solutions announced last week it has received Abbreviated New Drug Application (ANDA) approval from the Food and Drug Administration for its PET radiopharmaceutical sodium fluoride F 18 injection (18F NaF).

The ANDA approval means PETNET Solutions can now proceed with manufacturing and distributing 18F NaF across its network of radiopharmacies in the U.S.

18F NaF is indicated for “bone imaging to define areas of altered osteogenic activity, including metastatic disease from cancer,” according to a statement from Siemens.

PETNET Solutions is a wholly owned subsidiary of Siemens Healthcare.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.